title: Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
abstract: Tumor angiogenesis is one of the main pathways targeted to treat cancer. Bevacizumab added survival benefit when combined with platinum-based chemotherapy in NSCLC. Recently, Phase III trials showed survival benefit when anti-angiogenic drugs are added to docetaxel as second-line treatment for NSCLC. These anti-angiogenic agents include nintedanib and ramucirumab, a tyrosine-kinase inhibitor and a monoclonal antibody, respectively, which target receptors involved in angiogenesis. These studies have some similarities and differences. We propose a new algorithm for treatment sequences in performance status 0-1 patients with non-oncogene-addicted NSCLC type adenocarcinoma. Indeed clearer scientific evidences are available for this subgroup of patients.
authors.affiliation: a 1 Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo , Palermo, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Bronte
authors.affiliation: a 1 Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo , Palermo, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Passiglia
authors.affiliation: a 1 Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo , Palermo, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Galvano
authors.affiliation: b 2 Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo , Via del Vespro 129 - 90127 Palermo, Italy +39 091 655 2500 ; +39 091 655 4529 ; antonio.russo@usa.net.
authors.forename: Antonio
authors.initials: A
authors.lastname: Russo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000379:methods / Q000639:trends; D000077143:Docetaxel; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use; D035703:Therapies, Investigational / Q000592:standards / Q000639:trends*; D000096662:Ramucirumab
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000077143:Docetaxel; D007211:Indoles; D047428:Protein Kinase Inhibitors; D043823:Taxoids; D000096662:Ramucirumab; C530716:nintedanib
keywords: NSCLC; angiogenesis; docetaxel; nintedanib; ramucirumab